APA (7th ed.) Citation

G, O., N, A., F, B., A, B., C, B., I, C., . . . LF, H. (2018). Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis. ChemMedChem, 13(4), 321. https://doi.org/10.1002/cmdc.201700758

Chicago Style (17th ed.) Citation

G, Ouvry, et al. "Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis." ChemMedChem 13, no. 4 (2018): 321. https://doi.org/10.1002/cmdc.201700758.

MLA (9th ed.) Citation

G, Ouvry, et al. "Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis." ChemMedChem, vol. 13, no. 4, 2018, p. 321, https://doi.org/10.1002/cmdc.201700758.